PUBLICATION

The expanding role of fish models in understanding non-alcoholic fatty liver disease

Authors
Asaoka, Y., Terai, S., Sakaida, I., and Nishina, H.
ID
ZDB-PUB-130708-27
Date
2013
Source
Disease models & mechanisms   6(4): 905-914 (Review)
Registered Authors
Keywords
none
MeSH Terms
  • Animals
  • Animals, Genetically Modified
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Fatty Liver/pathology*
  • Fishes/genetics
  • Fishes/metabolism*
  • Humans
  • Non-alcoholic Fatty Liver Disease
(all 9)
PubMed
23720231 Full text @ Dis. Model. Mech.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excessive fat accumulates in the liver of an individual who has not consumed excessive alcohol. Non-alcoholic steatohepatitis (NASH), a severe form of NAFLD, can progress to hepatic cirrhosis and/or hepatocellular carcinoma (HCC). NAFLD is considered to be a hepatic manifestation of metabolic syndrome, and its incidence has risen worldwide in lockstep with the increased global prevalence of obesity. Over the last decade, rodent studies have yielded an impressive list of molecules associated with NAFLD and NASH pathogenesis. However, the identification of currently unknown metabolic factors using mammalian model organisms is inefficient and expensive compared with studies using fish models such as zebrafish (Danio rerio) and medaka (Oryzias latipes). Substantial advances in unraveling the molecular pathogenesis of NAFLD have recently been achieved through unbiased forward genetic screens using small fish models. Furthermore, these easily manipulated organisms have been used to great advantage to evaluate the therapeutic effectiveness of various chemical compounds for the treatment of NAFLD. In this Review, we summarize aspects of NAFLD (specifically focusing on NASH) pathogenesis that have been previously revealed by rodent models, and discuss how small fish are increasingly being used to uncover factors that contribute to normal hepatic lipid metabolism. We describe the various types of fish models in use for this purpose, including those generated by mutation, transgenesis, or dietary or chemical treatment, and contrast them with rodent models. The use of small fish in identifying novel potential therapeutic agents for the treatment of NAFLD and NASH is also addressed.

Genes / Markers
Marker Marker Type Name
ahcyGENEadenosylhomocysteinase
cdiptGENECDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol synthase)
cnr1GENEcannabinoid receptor 1
fgfr1aGENEfibroblast growth factor receptor 1a
krasGENEv-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
sec63GENESEC63 homolog, protein translocation regulator
slc16a6aGENEsolute carrier family 16 member 6a
stk11GENEserine/threonine kinase 11
trappc11GENEtrafficking protein particle complex subunit 11
yy1bGENEYY1 transcription factor b
1 - 10 of 10
Show
Figures
Figure Gallery (2 images)
Show all Figures
Expression
Phenotype
No data available
Mutations / Transgenics
Allele Construct Type Affected Genomic Region
gz21TgTransgenic Insertion
    gz25TgTransgenic Insertion
      gz26TgTransgenic Insertion
        hi559TgTransgenic Insertion
        hi1532bTgTransgenic Insertion
        hu1960
          Point Mutation
          hu1968
            Point Mutation
            p14nb
              Point Mutation
              pd1TgTransgenic Insertion
                s951
                  Insertion
                  1 - 10 of 17
                  Show
                  Human Disease / Model
                  Sequence Targeting Reagents
                  No data available
                  Fish
                  Antibodies
                  No data available
                  Orthology
                  No data available
                  Engineered Foreign Genes
                  Marker Marker Type Name
                  EGFPEFGEGFP
                  GFPEFGGFP
                  1 - 2 of 2
                  Show
                  Mapping